Discerning Clinical Responses in Breast Cancer Based Upon Molecular Signatures.

Discerning Clinical Responses in Breast Cancer Based Upon Molecular Signatures. Am J Pathol. 2017 Aug 16;: Authors: Coleman WB, Anders CK Abstract Breast cancer represents a heterogeneous collection of diseases with disparate clinical behaviors, responses to treatment, and patient outcomes, despite common histopathological features at diagnosis. Examination of molecular signatures of breast cancer (based upon complex gene expression patterns) enabled identification of several intrinsic molecular subtypes: luminal A, luminal B, HER2-enriched, and basal-like. The intrinsic subtypes are associated with measures of clinical aggressiveness, but do not perfectly predict patient outcomes. Several molecular signatures have been developed for prediction and prognostication of breast cancer outcomes. This review describes the molecular classification of breast cancer and the use of predictive/prognostic molecular signatures for guiding treatment decisions in breast cancer patients. PMID: 28822803 [PubMed - as supplied by publisher]
Source: The American Journal of Pathology - Category: Pathology Authors: Tags: Am J Pathol Source Type: research